Announcements Trials
Browse Landscape

Phase

Phase NA 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 51Gastrointestinal 8Breast 8Thoracic 6Gynecologic 4Endocrine 1

Conditions

Multiple Endocrine Neoplasia Type 1 3Prostatic Neoplasms 1Pancreatic Neoplasms 1Obesity 1Neuroendocrine Tumors 1Motor Activity 1Carcinoma, Neuroendocrine 1Breast Neoplasms, Male 1Breast Neoplasms 1

Interventions

atezolizumab 2Trastuzumab 2Magnetic Resonance Spectroscopy 2vandetanib 1tivozanib 1tipifarnib 1temsirolimus 1romidepsin 1pembrolizumab 1pasireotide 1methyl hydroxyethyl cellulose 1gadoteridol 1gadoterate meglumine 1gadolinium ethoxybenzyl DTPA 1gadodiamide 1gadobutrol 1gadobenic acid 1entinostat 1Walking 1Vinorelbine 1Suramin 1Standard of Care 1Specimen Handling 1Sirolimus 1Ritonavir 1Respiratory Therapy 1Radiotherapy 1Quality of Life 1Patient Reported Outcome Measures 1Paclitaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Prostatic Neoplasms × Standard of Care × Endocrine × Clear all
NCT02957981 2023-09-13

GEM

Georgetown University

Phase NA Completed
63 enrolled
BreastEndocrineGastrointestinalGenitourinary

Breast Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Breast Neoplasms, Male, Multiple Endocrine Neoplasia Type 1

Data powered by HemOnc (CC BY 4.0) Colophon âš¡